 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
AIDS Project Los Angeles
Limited T-20 Compassionate Use Program Launches in OctoberSeptember/October 2002 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Individuals with HIV who are in need of a salvage therapy and who meet certain criteria may be able to access T-20, also known as Fuzeon, through a compassionate use program expected to begin in October.
T-20, a member of a new class of drugs called fusion inhibitors, is administered by injection twice a day. FDA approval of the drug is expected soon. Only 600 slots in the program are available. Individuals enrolling in the program must be 6 years old or older, have a viral load greater than 10,000 copies and a CD4 count of less than 100 cells/mm3 while on highly active antiretroviral therapy. Individuals must also "be limited by the currently commercial available antiretroviral agents as per the judgment of the investigator," according to a letter announcing the program. Individuals interested in the program should consult their physicians.
Back to the September/October 2002 issue of Positive Living.
This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.
|
E-Mail
Printable Single-Page
Glossary
Share
